| Name | Xylometazoline hydrochloride |
| Description | Xylometazoline hydrochloride (Xylometazoline HCl) is an α-adrenoceptor agonist usually used as nasal decongestant. |
| In vitro | Xylometazoline is an α-adrenoceptor agonist commonly used as nasal decongestant, exhibits highest potency at α2B-adrenoceptor subtype with EC50 of 99 μM. Xylometazoline binds at adrenoceptor subtypeα1A, α1B, α1D, α2A, α2B, α2C with IC50 of 0.08, 0.56, 0.45, 0.98, 1.8, 0.22 μM, repectively. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 16 mg/mL (56.97 mM), Sonication is recommended. Ethanol : 52 mg/mL (185.16 mM), Sonication is recommended. H2O : 51 mg/mL (181.6 mM), Sonication is recommended.
|
| Keywords | α2C-adrenergic receptor | α2B-adrenergic receptor | α2A-adrenergic receptor | α1D-adrenergic receptor | α1B-adrenergic receptor | α1A-adrenergic receptor | Xylometazoline hydrochloride | Xylometazoline Hydrochloride | Xylometazoline | runny nose | nose stuffiness | Inhibitor | inhibit | increase nasal airflow | constrict nasal blood vessels | Beta Receptor | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Phenylephrine hydrochloride | Amitriptyline hydrochloride | Isoprenaline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |